Status:
COMPLETED
SGLT2i and Incretin and CRTd.
Lead Sponsor:
University of Campania Luigi Vanvitelli
Conditions:
Type 2 Diabetes Mellitus
Heart Failure
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Incretin therapy and sodium-glucose- transporter2 inhibitors (SGLT2i) are a treatment for type 2 diabetes (T2DM) affected by heart failure (HF) and treated with cardiac resynchromization therapy (CRT)...
Eligibility Criteria
Inclusion
- aged more than 18 years, with clinical hystory of T2DM non insulin dependent, and diagnosed failing heart with depressed ejection fraction; CRTd recipients.
Exclusion
- T2DM in insuline therapy; renal impairment, chronic inflammatory and systemic diseases; neoplastic diseases.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03282136
Start Date
September 1 2017
End Date
September 1 2024
Last Update
June 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Raffaele Marfella
Naples, Italy, Italy, 80128